DRMA (Dermata Therapeutics Inc.) stock is in for a key growth catalyst

In the latest session, Dermata Therapeutics Inc. (NASDAQ: DRMA) closed at $0.64 down -5.97% from its previous closing price of $0.69. In other words, the price has decreased by -$0.0409 from its previous closing price. On the day, 234387 shares were traded. DRMA stock price reached its highest trading level at $0.6742 during the session, while it also had its lowest trading level at $0.6200.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Ratios:

For a deeper understanding of Dermata Therapeutics Inc.’s stock, let’s take a closer look at its various ratios.

Upgrades & Downgrades

Stock Price History:

Over the past 52 weeks, DRMA has reached a high of $3.19, while it has fallen to a 52-week low of $0.44. The 50-Day Moving Average of the stock is 0.6372, while the 200-Day Moving Average is calculated to be 0.8134.

Shares Statistics:

For the past three months, DRMA has traded an average of 232.95K shares per day and 216.84k over the past ten days. A total of 12.10M shares are outstanding, with a floating share count of 8.09M. Insiders hold about 2.00% of the company’s shares, while institutions hold 1.60% stake in the company. Shares short for DRMA as of Oct 13, 2022 were 78.97k with a Short Ratio of 0.18M, compared to 39.96k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.78% and a Short% of Float of 1.22%.

Earnings Estimates

There are 1 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.22 for the current quarter, with a high estimate of -$0.22 and a low estimate of -$0.22, while EPS last year was -$0.86. The consensus estimate for the next quarter is -$0.23, with high estimates of -$0.23 and low estimates of -$0.23.

Analysts are recommending an EPS of between -$1.02 and -$1.02 for the fiscal current year, implying an average EPS of -$1.02. EPS for the following year is -$1.4, with 1 analysts recommending between -$1.4 and -$1.4.